1.54 -0.08 (-4.94%) | 11-01 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.09 | 1-year : | 2.44 |
Resists | First : | 1.78 | Second : | 2.09 |
Pivot price | 1.02 | |||
Supports | First : | 1.11 | Second : | 0.68 |
MAs | MA(5) : | 1.32 | MA(20) : | 0.94 |
MA(100) : | 0.76 | MA(250) : | 0.95 | |
MACD | MACD : | 0.1 | Signal : | 0 |
%K %D | K(14,3) : | 72.5 | D(3) : | 66.4 |
RSI | RSI(14): 74.7 | |||
52-week | High : | 1.78 | Low : | 0.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QNCX ] has closed below upper band by 3.2%. Bollinger Bands are 435.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.72 - 1.73 | 1.73 - 1.74 |
Low: | 1.41 - 1.42 | 1.42 - 1.42 |
Close: | 1.53 - 1.54 | 1.54 - 1.55 |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Wed, 30 Oct 2024
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Tue, 29 Oct 2024
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
Tue, 29 Oct 2024
Rodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Mon, 14 Oct 2024
Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Tue, 03 Sep 2024
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Tue, 03 Sep 2024
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 43 (M) |
Shares Float | 35 (M) |
Held by Insiders | 13.7 (%) |
Held by Institutions | 25.2 (%) |
Shares Short | 1,910 (K) |
Shares Short P.Month | 1,960 (K) |
EPS | -1.26 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.09 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -16.5 % |
Return on Equity (ttm) | -79.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.68 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -28 (M) |
Levered Free Cash Flow | -8 (M) |
PE Ratio | -1.23 |
PEG Ratio | -0.1 |
Price to Book value | 1.41 |
Price to Sales | 0 |
Price to Cash Flow | -2.39 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |